Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CALCA | P06881 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6017731 | 0.88 | KCNE1 (0.37) | KCNE1CCR1KCNQ1SMN1; SMN2CALCA | |
| SCHEMBL6017768 | 0.87 | CNR1 (0.44) | CNR1 | |
| SCHEMBL6017999 | 0.86 | KCNE1 (0.51) | KCNE1CCR1KCNQ1SMN1; SMN2CALCA | |
| SCHEMBL6017949 | 0.86 | CNR1 (0.38) | KCNE1CCR1KCNQ1CALCAKMT2A | |
| SCHEMBL6018587 | 0.86 | SMN1; SMN2 (0.51) | KCNE1CCR1KCNQ1SMN1; SMN2KMT2A | |
| SCHEMBL6018991 | 0.82 | SMN1; SMN2 (0.53) | KCNE1CCR1KCNQ1SMN1; SMN2CALCA | |
| SCHEMBL6017760 | 0.80 | SMN1; SMN2 (0.57) | KCNE1CCR1KCNQ1SMN1; SMN2KMT2A | |
| SCHEMBL1150766 | 0.80 | SMN1; SMN2 (0.50) | KCNE1CCR1KCNQ1SMN1; SMN2CALCA | |
| SCHEMBL6017686 | 0.80 | KCNE1 (0.55) | KCNE1CCR1KCNQ1SMN1; SMN2CALCA | |
| SCHEMBL6017751 | 0.79 | KCNE1 (0.51) | KCNE1CCR1KCNQ1SMN1; SMN2CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-18 | — | — | US | claimed |
| US-7037908-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-18 | — | — | US | disclosed |
| WO-2004096128-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | DUT, CDK6, TYMS | KCNE1 3647/4885CCR1 1187/4885KCNQ1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.